Molemap

What Molemap does

MoleMap is an Australia- and New Zealand-based skin cancer detection and surveillance company founded around 2005, operating a network of more than 40 company-owned and partner clinics across six Australian states and New Zealand. Its core service is a tiered skin check — SkinCheck, SkinCheck+, and the premium Full Body MoleMap — delivered through a proprietary nurse-led model in which specially trained registered nurses called melanographers perform head-to-toe assessments and capture dermoscopic images that are then independently reviewed by accredited dermatologists. The clinical workflow is augmented by AI-assisted image analysis and total-body photography for longitudinal mole mapping, with AI flags feeding into dermatologist diagnosis rather than serving as a standalone output. The business also offers skin cancer treatment at select clinics and sells workplace skin-check programs to corporate clients.

MoleMap generates revenue through fee-for-service clinical consultations, with the Full Body MoleMap tier operating on an annual subscription cadence that bundles 12 months of free spot checks against a photographic baseline, while SkinCheck and SkinCheck+ are positioned as one-time visits. Self-serve online booking (book.molemap.net.au), a national phone number, GP referrals, and an enterprise field-sales motion for workplace programs together make up a blended go-to-market. The consumer segment dominates patient volume and is augmented by corporate OHS contracts and a formal GP-referral pathway. Total lifetime scale is reported at over 500,000 patients and 13 million moles diagnosed across roughly two decades of operation.

At the operating level, leadership includes CEO Michelle Aquilina and CMO Dr Lorna Claydon, with 2024 appointments of COO Ben Avery, CRO Jaime Schell, and Group CFO Mark Stokes suggesting preparation for further commercial scaling or a prospective capital event. The company has no public funding history in the supplied data, is privately held, and reported revenue is not disclosed. Customer-facing technology includes the My MoleMap patient portal and Afterpay payment integration at participating clinics; partnerships include a December 2024 alliance with skincare brand Avène for co-marketed skin-cancer awareness.

Name

Molemap

Legal name

MoleMap

Website

https://molemap.net.au

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

MoleMap is an Australian and New Zealand skin cancer detection service that uses nurse-led melanographers, AI-assisted dermoscopic imaging, and dermatologist review to deliver tiered skin checks across 40+ clinics. It serves individual consumers, corporate workplace programs, and GP-referred patients.

Ownership category

akta.pro rank

Product category

Skin Cancer Screening and Dermatology Surveillance Services

NAICS

Diagnostic Imaging Centers (621512)

SIC

Services-Health Services (8000)

akta.pro primary industry

General & Medical Dermatology (HLAKACAA)

akta.pro secondary industry

Procedural Dermatology (Office-Based Surgery) (HLAKACAG)

Keywords

• Skin cancer screening
• Mole mapping services
• Dermatology surveillance
• Melanoma detection
• Skin health checks

Headquarters

HQ city

South Melbourne

HQ country

Australia

HQ region

Oceania

Offices24 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Professional Skin Cancer Screening Services: MoleMap generates revenue through fee-for-service clinical consultations for skin cancer detection and monitoring. Patients pay per appointment based on the service tier selected (SkinCheck, SkinCheck+, or Full Body MoleMap). Revenue is primarily one-time per visit but includes an ongoing monitoring component for Full Body MoleMap subscribers who return for annual reviews and spot checks. Afterpay is accepted at participating clinics to break costs into interest-free installments.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

MoleMap is an Australian-headquartered skin cancer detection and surveillance provider that operates a network of more than 40 clinics across Australia and New Zealand. Its core service is total body mole mapping, in which trained melanographers capture full-body and dermoscopic images of a patient's skin and have them reviewed by dermatologists, supported by AI-assisted image analysis to identify suspicious or changing lesions. Patients receive structured surveillance, follow-up imaging, and referrals to skin cancer treatment where lesions of concern are identified.

Product overview

MoleMap is a specialized skin cancer detection, diagnosis, proactive monitoring, and treatment service operating across Australia and New Zealand. The core offering is a three-tiered skin check service: Full Body MoleMap (most comprehensive with full body imaging, dermoscopic mole imaging, proactive mole mapping and monitoring, dermatologist diagnosis, and 12 months of free spot checks), SkinCheck+ (full body imaging with dermatologist diagnosis), and SkinCheck (targeted skin assessment with dermatologist review of at-risk moles). At the clinical level, a melanographer (registered nurse with specialized skin cancer training) performs the skin examination and dermoscopic imaging, with any suspicious moles then sent for accredited dermatologist diagnosis—a dual-expert review process. Select clinics also provide Skin Cancer Treatment services. The service is delivered through a network of over 40 partner clinics across Australian states and territories, with a patient-facing portal (My MoleMap) and online booking system. AI analysis is applied to dermoscopic images to support early detection, and payment options include Afterpay at participating clinics.

Differentiator

Problem solved

Functional benefit

Products and services

• Full Body MoleMap Comprehensive total-body mole mapping service in which a melanographer captures standardized full-body and dermoscopic images that are reviewed by a dermatologist, with the option of ongoing surveillance visits to track mole changes over time. Targeted at adults at higher risk of melanoma and skin cancer who want a structured early-detection program rather than a one-off check.
• SkinCheck A focused mole check of one or more specific spots of concern identified by the patient, including dermoscopic imaging and clinical assessment. Aimed at people who want a quicker, lower-cost assessment of a particular mole rather than a full-body program.
• SkinCheck+ An intermediate skin check tier offering more extensive imaging and clinical assessment than the basic SkinCheck, for patients who want a broader review without committing to the full-body MoleMap program.
• Workplace Skin Checks Employer-sponsored skin cancer screening program delivered at MoleMap clinics or on-site, focused on outdoor and UV-exposed workforces. Sold to HR, WHS/OHS, and People & Culture teams as an occupational health and employee wellbeing benefit.
• Skin Cancer Treatment Follow-on clinical management of suspicious or confirmed skin cancers identified during MoleMap screening, including treatment planning and procedures. For patients requiring intervention after a screening flags a lesion of concern.
• My MoleMap patient portal Online portal giving patients secure access to their mole imaging history and surveillance results, enabling them to track changes over time and review past reports between MoleMap visits.

Quantifiable outcome

• 95% of melanomas are treatable if spotted very early
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature4 records

Partnerships

One partnership is on record.

• AvèneminorGTM or Marketing Partner · 3 December 2024MoleMap and Avène (a skincare brand) joined forces in December 2024 in a partnership focused on the fight against skin cancer in Australia. The collaboration likely involves co-markaging and cross-promotion of skin cancer awareness and prevention, combining MoleMap's detection expertise with Avène's sun protection and skincare product range.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Others

• Doctoralia: Global healthcare booking and directory platform owned by Docplanner, operating in Australia. Comparable as a consumer channel for booking dermatology and specialist appointments, though not a direct clinical competitor to MoleMap.

Emerging players

• Skin Analytics: UK-based AI dermatology company whose DERM device uses computer vision to triage skin lesions in primary care. Comparable to MoleMap in deploying AI dermoscopic analysis within skin cancer detection workflows, though distributed as a device rather than a clinic service.
• SkinVision: Amsterdam-based AI skin cancer detection app that uses smartphone camera-based image analysis for risk assessment and triage. Comparable to MoleMap's AI-assisted mole analysis component, with a consumer-direct mobile delivery model rather than clinic-based.
• DermaSensor: US-based developer of a handheld AI-powered spectroscopy device for primary care skin cancer triage. Comparable technology layer to MoleMap's AI dermoscopic analysis, but positioned as a point-of-care device for GPs rather than a dedicated clinic.
• First Derm: Teledermatology platform offering online dermatologist consultations and AI-assisted triage of skin lesions via smartphone images. Comparable consumer skin cancer triage use case to MoleMap, with an asynchronous remote model rather than a physical clinic network.

Broad incumbents

• FotoFinder Systems: German-headquartered manufacturer of total body photography and AI-assisted mole mapping systems used by dermatology clinics worldwide. Directly comparable technology stack to MoleMap's total body photography and AI mole analysis capability, sold as enterprise equipment rather than a service.
• Canfield Scientific: US-headquartered provider of dermoscopic imaging systems, total body photography platforms (e.g., VECTRA), and clinical image management software used by dermatology practices globally. Comparable underlying technology supplier to MoleMap's imaging infrastructure, though operating as a B2B vendor rather than a clinical service.

Direct peers

• MoleSafe: New Zealand-founded mole mapping and skin surveillance service using total body dermoscopic photography and dermatologist review. Direct peer with overlapping clinical methodology and overlapping Australasian geographic footprint.
• National Skin Cancer Centres: Australian network of skin cancer clinics providing full-body skin checks, digital mole mapping, and dermatologist-led diagnosis. Directly comparable to MoleMap in service model, target customer, and clinical workflow.
• SunDoctors: Australia's largest dedicated skin cancer clinic chain, offering skin checks, mole mapping, and surgical treatment across a multi-site network. Directly competes with MoleMap on consumer skin cancer screening with similar pricing tiers and clinic-based delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/molemap
• Facebookfacebook.com/molemapaustralia
• LinkedInlinkedin.com/company/molemap-australia-new-zealand

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molemap